stockrowAIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024.
- Revenue
- +4.00%
- EPS
- +88.3%
- Free cash flow
- −167.5%
Quarter to June 2026, against a year earlier
Follow AIM
Alert me
AIM ImmunoTech Inc. (AIM) EV/Sales
As of 6 November 2026, AIM ImmunoTech Inc. (AIM) trades at a EV/Sales of −71.4×. Over the past ten years it has ranged from −157× (December 2022) to 487× (July 2021); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.0× | (63.52%) |
| FY2024 | 44.0× | (17.46%) |
| FY2023 | 53.3× | — |
| FY2022 | −126× | — |
| FY2021 | −32.7× | — |
| FY2020 | 123× | — |
| FY2019 | −1.5× | — |
| FY2018 | 23.6× | 7.43% |
| FY2017 | 21.9× | (78.31%) |
| FY2016 | 101× | 41.09% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −49.8× | — |
| Mar 2026 | −30.5× | — |
| Dec 2025 | 16.0× | (51.42%) |
| Sep 2025 | 33.0× | (34.47%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. | −71.4× |
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| EVGN Evogene Ltd. compare | −3.6× |
| CRIS Curis, Inc. compare | −0.3× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| ORGS Orgenesis Inc. compare | 16.9× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)